In the News
Cardiology guidance supports use of SGLT-2 inhibitors, GLP-1 receptor agonists for CV benefits in diabetes
Evidence on sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists indicates that these drugs can be used not just for glucose control but for cardiovascular (CV) risk reduction in patients with type 2 diabetes, according to a new expert pathway.
SGLT-2 inhibitors associated with increased risk for diabetic ketoacidosis
A cohort study found a threefold increase in the risk for diabetic ketoacidosis with sodium-glucose cotransporter-2 (SGLT-2) inhibitors compared to dipeptidyl peptidase-4 (DPP-4) inhibitors, with possible variation by severity or duration of diabetes.
Patient-led titration of basal insulin appears effective in type 2 diabetes
A meta-analysis of six studies found that patient-led titration was associated with lower HbA1c and fasting plasma glucose levels than physician-led titration, although hypoglycemia risk and body weight were slightly higher.
MKSAP quiz: Adverse medication effects
This month's quiz asks readers to evaluate a man with type 2 diabetes who is taking glipizide and empagliflozin and has nausea, vomiting, and fatigue.
Spotlight on amputations
Recent studies analyzed data on lower-extremity amputations among patients with diabetes, including recent trends in this complication and its associated mortality, effects of the pandemic, and relationships with diabetes drugs.
Canagliflozin can lead to statin toxicity, case report finds
A case report describes a patient who had taken rosuvastatin for five years and had new muscle pain and difficulty ambulating two weeks after initiation of canagliflozin.
Some glucose-lowering drugs reduce risk for major adverse cardiac events
An umbrella review found cardiovascular benefits from sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, but an ACP Journal Club commentary cautioned that included patients were on a wide array of background treatments.
CGM system reduced hypoglycemia in high-risk inpatients with type 2 diabetes
In a randomized trial, insulin-treated patients who had real-time continuous glucose monitoring (CGM) data sent to a nursing station experienced fewer hypoglycemic events than those who received point-of-care blood glucose testing.